Drug Interactions

Lecture Learning Outcomes
By the end of this lecture, students will be able to:
• Define drug interactions
• Distinguish the terms object drug and precipitant drug in drug-drug interactions
• Classify drug interactions as pharmaceutical, pharmacokinetic, or pharmacodynamic.
• Explain representative chemical and biological mechanisms that underlie drug interactions
• Predict the clinical consequence of selected common drug interactions.
• Apply a practical approach to preventing and managing drug interactions.

2. What Is a Drug Interaction?

A drug interaction occurs when one substance changes the concentration or effect of another drug.

Drug–drug interactions (DDIs): Clinically meaningful alterations in the effects of drugs administered together.

Term

Meaning

Object drug / victim drug

Drug whose concentration or effect changes

Precipitant / perpetrator

Drug, food, beverage, or supplement causing the change

A medical condition can also alter a drug’s concentration or the patient’s response to it.

. Three Categories of Drug Interactions

Category

What changes?

Example

Pharmaceutical

Drugs interact before administration

Incompatibility when drugs mix in an IV line

Pharmacokinetic: PK

Drug concentration changes through ADME

Rifampin lowers warfarin exposure

Pharmacodynamic: PD

Drug effects interact at the target, cell, or tissue level

Opioids plus alcohol increase CNS depression

Key distinction:

  • PK interaction: Changes drug exposure.

  • PD interaction: Changes drug effects without necessarily changing concentration.

4. When Do Interactions Matter?

An interaction is clinically important when it changes the patient’s benefit or risk from treatment.

Harmful interactions

May cause:

  • Increased toxicity

  • Reduced efficacy

  • Treatment failure

Risk is especially important with:

  • Narrow-therapeutic-index drugs

  • Polypharmacy: Use of multiple medications

  • Impaired kidney function

  • Impaired liver function

Beneficial interactions

Some interactions are intentional.

Combination therapy may:

  • Increase therapeutic benefit.

  • Reduce adverse effects.

  • Produce useful synergy.

Pharmacokinetic Interactions

5. PK Interactions and ADME

The precipitant drug changes the absorption, distribution, metabolism, or excretion of the object drug.

ADME step

How an interaction might change drug exposure

Absorption

Changes the amount or rate of drug reaching systemic circulation

Distribution

Changes free-drug concentration or tissue exposure

Metabolism

Inhibits or induces Enzymatic drug clearance or activation

Excretion

Changes Renal, biliary, or transporter-mediated elimination

6. Mechanisms That Alter Absorption

The lecture identifies four major mechanisms:

  1. Changes in GI pH

  2. Changes in GI motility

  3. Ionic interactions or complexation

  4. Changes in drug transporter activity

7. GI pH and Drug Ionization

Many drugs are weak organic acids or bases that exist in ionized and un-ionized forms in an aqueous environment.

Weak acids

\[ AH \rightleftharpoons A^- + H^+ \]

  • AH: Un-ionized form

  • A⁻: Ionized form

Weak bases

\[ B + H^+ \rightleftharpoons BH^+ \]

  • B: Un-ionized form

  • BH⁺: Ionized form

Why ionization matters

The un-ionized form which is more lipophilic generally crosses lipid membranes more readily across cell membranes.

In an acidic environment: Low pH

More H⁺ is present.

Drug type

Equilibrium change

Effect on passive membrane crossing

Weak acid

More un-ionized AH

More favorable

Weak base

More ionized BH⁺

Less favorable

When pH increases

  • Weak acids become more ionized.

  • Weak bases become less ionized.

The slide therefore states that alkalinizing drugs, such as antacids, may:

  • Decrease absorption of weak acids.

  • Facilitate absorption of weak bases.

8. GI Motility and Gastric Emptying

Gastric emptying determines how quickly an oral drug reaches the small intestine.

The small intestine is the main absorption site for most drugs.

A precipitant drug that changes GI motility can change the rate of absorption.

Metoclopramide + acetaminophen

Metoclopramide:

  • Prokinetic antiemetic.

  • Increases gastric emptying.

Interaction:

Faster delivery of acetaminophen to the small intestine → faster absorption → earlier onset.

Role

Drug

Object

Acetaminophen

Precipitant

Metoclopramide

Methadone + oral drugs

Methadone:

  • Fully synthetic opioid receptor full agonist.

  • Decreases GI motility.

  • Delays gastric emptying.

Consequence: May delay or alter absorption of coadministered oral drugs.

Key point: Changing absorption rate does not always change total exposure.

Although the slide title says “distribution,” these examples describe absorption.

9. Ionic Interactions and Complexation

Some substances bind drugs in the GI lumen, leaving less drug available for absorption.

A. Metal-ion chelation

Tetracyclines and fluoroquinolones, including ciprofloxacin, can form poorly absorbed complexes with:

  • Calcium

  • Magnesium

  • Aluminum

  • Iron

  • Zinc

Common precipitants:

  • Antacids

  • Mineral supplements

  • Multivitamins

Result:

Complex formation → decreased antibiotic absorption → possible treatment failure.

Ciprofloxacin timing example

The lecture specifies administering ciprofloxacin:

  • At least 2 hours before, or

  • At least 6 hours after

10. Protein Binding: Free Drug Matters

The unbound drug fraction is available to:

  • Cross membranes

  • Bind targets

  • Undergo clearance

Protein-binding displacement

A second drug can displace a highly protein-bound drug from albumin.

Displacement → transient increase in free-drug concentration.

However, the extra free drug may also:

  • Distribute into tissues more rapidly.

  • Be cleared more rapidly.

Therefore, displacement alone rarely causes a sustained interaction.

NSAID examples

The slide describes NSAIDs as highly albumin-bound, often greater than 95%.

NSAIDs can displace drugs such as:

  • Warfarin

  • Methotrexate

in laboratory studies.

More important clinical mechanisms

Combination

Major concern

NSAID + methotrexate

Reduced renal clearance → increased methotrexate toxicity

NSAID + warfarin

Additive effects on bleeding through different mechanisms

NSAIDs and renal perfusion

NSAID inhibits prostaglandin synthesis → afferent arteriolar constriction → reduced renal blood flow and GFR → potentially reduced methotrexate clearance.

Concern increases when displacement occurs alongside other PK/PD interactions or involves a narrow-therapeutic-index drug.

11. Altered Drug Metabolism

The major enzyme family discussed is cytochrome P450: CYP.

Inhibition versus induction

Change

Typical effect

Typical onset

Enzyme inhibition

Increased parent-drug exposure; decreased formation of an active metabolite

Often hours to a few days

Enzyme induction

Decreased parent-drug exposure; increased metabolite formation

Usually days to weeks

The clinical result depends on whether the parent drug, metabolite, or both are active or toxic.

Common CYP examples

Enzyme

Examples mentioned

CYP3A4

Common pathway in drug interactions

CYP2D6

Metoprolol, codeine

CYP2C9

Warfarin, some NSAIDs

CYP2C19

Omeprazole, diazepam

12. CYP Inhibition Examples

A. Amiodarone + warfarin

  • Object: Warfarin

  • Precipitant: Amiodarone

  • Mechanism: CYP2C9 inhibition

Sequence:

Less warfarin metabolism → increased warfarin exposure → increased bleeding risk.

B. Paroxetine + codeine

  • Object: Codeine

  • Precipitant: Paroxetine, an SSRI antidepressant

  • Mechanism: CYP2D6 inhibition

Normally:

\[ \text{Codeine}\xrightarrow{\text{CYP2D6}}\text{Morphine} \]

With inhibition:

Less morphine formation → reduced analgesia.

Important: Enzyme inhibition can reduce efficacy when metabolism is needed for drug activation.

C. Grapefruit + susceptible oral CYP3A substrates

  • Object: A susceptible oral CYP3A substrate

  • Precipitant: Grapefruit products

  • Mechanism: Inhibition of intestinal CYP3A4

The slide identifies furanocoumarins as compounds responsible for this inhibition.

Consequence: Higher oral drug exposure and increased toxicity risk.

13. CYP Induction Examples

Induction increases enzyme expression or activity and can lower concentrations of susceptible parent drugs.

A. Rifampin + warfarin

Rifampin:

  • Antibiotic used for tuberculosis.

  • Strong inducer of:

    • CYP3A4

    • CYP2C9

    • CYP2C19

    • P-gp

Consequence: Lower warfarin exposure → reduced anticoagulation.

B. St. John’s wort + susceptible drugs

St. John’s wort:

  • Herbal product used for depression.

  • Induces CYP3A4 and P-gp.

Consequence: Can lower exposure to susceptible drugs, including oral contraceptives, reducing effectiveness.

C. Chronic heavy alcohol use + acetaminophen

Chronic heavy alcohol exposure can increase CYP2E1 activity, partly through protein stabilization.

\[ \text{Acetaminophen}\xrightarrow{\text{CYP2E1}}\text{NAPQI} \]

NAPQI: Hepatotoxic acetaminophen metabolite.

Potential consequence: Increased formation of the toxic metabolite.

Enzyme–transporter overlap

The same precipitant can induce both CYP enzymes and MDR1/P-gp.

Therefore, one substance may affect both metabolism and transport.

14. Transporter-Mediated Interactions

Changes in transporter activity can alter:

  • Absorption

  • Tissue distribution

  • Excretion

Transporter

Typical location

Effect of inhibition

P-gp/ABCB1 and BCRP/ABCG2

Intestine, liver, kidney, blood–brain barrier

May increase absorption, systemic exposure, or tissue exposure

OAT and OCT

Renal proximal tubule

Can reduce active secretion and increase drug exposure

OATP

Liver and intestine

Can reduce hepatic uptake or alter intestinal absorption

Location matters: Inhibiting intestinal efflux, hepatic uptake, or renal secretion affects different steps in the drug’s path.

15. Quinidine + Digoxin

Digoxin

  • Cardiac glycoside.

  • Positive inotrope: Increases contractile force.

  • Inhibits cardiac Na⁺/K⁺-ATPase.

  • Has a narrow therapeutic index.

  • Not significantly metabolized by CYP enzymes.

  • Eliminated mainly unchanged through the kidneys; P-gp contributes to its transport and elimination.

Quinidine

  • Class IA antiarrhythmic.

  • Inhibits P-gp.

  • Also strongly inhibits CYP2D6.

Interaction mechanism

Normal P-gp:

  • Limits digoxin absorption.

  • Contributes to digoxin elimination.

Quinidine inhibits P-gp → less digoxin efflux → increased plasma digoxin concentration → increased toxicity risk.

Risk is greater with impaired renal function.

Role

Drug

Object

Digoxin

Precipitant

Quinidine

Main mechanism here

P-gp inhibition

Exam distinction: Quinidine inhibits CYP2D6, but the digoxin interaction is primarily a transporter interaction, not a CYP interaction.

Other P-gp inhibitors listed

  • Cyclosporine

  • Erythromycin

  • Verapamil

  • Curcumin

  • Lapatinib

Transporter interactions may affect several organs simultaneously.

16. NSAIDs + Methotrexate

Major concern: Reduced renal elimination, rather than protein displacement alone.

NSAID effect

Consequence for methotrexate

Inhibits renal prostaglandin synthesis

May reduce renal perfusion and glomerular filtration

Competes with renal organic anion transport

May reduce active tubular secretion

Net effect

Methotrexate accumulation and increased toxicity risk

NSAIDs shown:

  • Aspirin

  • Naproxen

  • Ibuprofen

Methotrexate:

  • Antifolate drug used in chemotherapy and other conditions.

  • Generally not considered a major MDR1/P-gp substrate.

Key point: Its transporter-related interaction here involves renal OAT transport, not primarily P-gp.

17. One Object Drug Can Have Multiple Interaction Sites

Atorvastatin example

Atorvastatin is handled by:

  • CYP3A4

  • P-gp

  • OATP transporters

Different precipitants can affect different parts of its disposition.

Precipitant

Mechanisms listed

Increase in atorvastatin plasma concentration shown

Cyclosporine

P-gp inhibition; OATP1B1 inhibition; weak CYP3A inhibition

8.7-fold

Clarithromycin

P-gp inhibition; strong CYP3A inhibition

4.4-fold

Diltiazem

P-gp inhibition; moderate CYP3A inhibition

51%

Gemfibrozil

OATP1B1 inhibition

35%

These values are the examples presented in the lecture.

Drug classes

  • Cyclosporine: Immunosuppressant

  • Clarithromycin: Antibiotic

  • Diltiazem: Calcium channel blocker

  • Gemfibrozil: Lipid-lowering drug

Question to ask: Where does the object drug travel, and which enzymes or transporters control each step?

Pharmacodynamic Interactions

18. Definition and Types

A pharmacodynamic interaction occurs when the precipitant changes the object drug’s activity at its site of action.

Drug concentrations may remain unchanged while effects:

  • Add together

  • Become greater than expected

  • Oppose one another

  • Create a new toxicity risk

Let E represent effect.

Type

Relationship

Meaning

Example

Additive / summation

\(E_{A+B}=E_A+E_B\)

Combined effect equals the sum

Acetaminophen + ibuprofen for analgesia

Synergistic / potentiation

\(E_{A+B}>E_A+E_B\)

Combined effect exceeds the expected sum

Trimethoprim + sulfamethoxazole

Antagonistic

\(E_{A+B}<E_A+E_B\)

One drug reduces the other’s effect

Metoprolol reduces dobutamine’s effect

19. Therapeutic Synergy: Trimethoprim + Sulfamethoxazole

These drugs inhibit different steps in the same bacterial folate pathway.

The lecture uses urinary tract infection treatment as an example.

Terms

  • PABA: Para-aminobenzoic acid

  • DHF: Dihydrofolate

  • THF: Tetrahydrofolate

Sequential blockade

Drug

Target/action

Result

Sulfamethoxazole

Competes with PABA at dihydropteroate synthase

Less downstream DHF formation

Trimethoprim

Inhibits dihydrofolate reductase: DHFR

Less conversion of DHF to THF

Block an earlier step + block a later step → synergistic inhibition of bacterial THF synthesis.

The slide also mentions sulfonamides such as sulfadiazine; the main combination illustrated is trimethoprim–sulfamethoxazole.

Selective toxicity

Sulfamethoxazole:

  • Humans do not synthesize folate from PABA.

  • Humans lack dihydropteroate synthase.

Trimethoprim:

  • Inhibits bacterial DHFR much more strongly than human DHFR.

20. Types of Antagonistic Interactions

A. Pharmacologic antagonism

Drugs act at the same receptor system.

Example:

  • Dobutamine: β₁ agonist.

  • Metoprolol: β₁ antagonist.

Metoprolol reduces dobutamine’s β₁-mediated effects.

B. Physiologic / functional antagonism

Drugs produce opposing physiological effects through different mechanisms.

Example:

  • Phenylephrine: α₁ agonist and vasopressor → raises blood pressure.

  • Nitroprusside: Vasodilator → lowers blood pressure.

C. Chemical antagonism

One drug directly binds or neutralizes another.

Example:

  • Protamine sulfate: Highly basic peptide drug.

  • Binds heparin and reverses its anticoagulant effect.

Type

Main idea

Pharmacologic

Opposing actions within the same receptor system

Physiologic

Opposing physiological effects

Chemical

Direct binding/neutralization

Antagonism may be harmful or intentional, such as reversal of anticoagulation.

21. PD Interactions That Increase Toxicity

Combination

Major risk

Why?

Anticoagulant + antiplatelet drug or NSAID

Bleeding

Multiple effects impair hemostasis or damage GI mucosa

Opioid, benzodiazepine, or alcohol combinations

Sedation and respiratory depression

Combined CNS depression

NSAID + corticosteroid

GI ulceration or bleeding

Combined impairment of GI protective mechanisms

CNS depressants and GABA-A

The lecture discusses:

  • Ethanol

  • Barbiturates, including phenobarbital

  • Benzodiazepines

These depress CNS activity and can enhance inhibitory GABA-A signaling.

Combined effects may be:

  • Additive, or

  • More than additive: Synergistic

GABA: Gamma-aminobutyric acid.

The receptor diagram shows distinct interaction sites for alcohol, barbiturates, and benzodiazepines.

Opioids also cause CNS and respiratory depression, but act primarily through opioid receptors rather than the GABA-A sites shown.

22. Practical Approach to Interactions

Learning objective application

For any interaction, work through:

  1. Identify the object drug.

    • Which drug’s exposure or effect changes?

  2. Identify the precipitant.

    • Include prescription drugs, OTC products, supplements, foods, and beverages.

  3. Classify the interaction.

    • Pharmaceutical, PK, or PD?

  4. Identify the mechanism.

    • Absorption, enzymes, transporters, receptor effects, or chemical binding?

  5. Predict the consequence.

    • Higher exposure, lower exposure, reduced activation, additive toxicity, or antagonism?

  6. Consider patient risk.

    • Narrow therapeutic index, kidney/liver impairment, and polypharmacy.

  7. Match prevention and monitoring to the mechanism.

    • Check compatibility before mixing drugs.

    • Separate administration when GI binding is the mechanism.

    • Consider an alternative combination or an appropriate dose adjustment.

    • Monitor relevant drug concentrations, clinical response, or toxicity.

23. Common Interaction Examples to Know

Combination

Main mechanism

Predicted consequence

Metoclopramide + acetaminophen

Increased gastric emptying

Faster absorption and earlier onset

Multivalent cations + ciprofloxacin

Chelation

Reduced antibiotic absorption

Cholestyramine + levothyroxine/warfarin

GI binding

Reduced absorption

Amiodarone + warfarin

CYP2C9 inhibition

Increased warfarin exposure and bleeding risk

Paroxetine + codeine

CYP2D6 inhibition

Less morphine formation and reduced analgesia

Grapefruit + susceptible oral CYP3A substrate

Intestinal CYP3A4 inhibition

Increased drug exposure

Rifampin + warfarin

Enzyme induction

Reduced warfarin exposure and anticoagulation

St. John’s wort + susceptible oral contraceptive

CYP3A4/P-gp induction

Reduced exposure and effectiveness

Chronic heavy alcohol use + acetaminophen

Increased CYP2E1 activity

Potentially increased NAPQI formation

Quinidine + digoxin

P-gp inhibition

Increased digoxin exposure and toxicity risk

NSAID + methotrexate

Reduced renal clearance

Methotrexate accumulation

Metoprolol + dobutamine

Pharmacologic antagonism

Reduced dobutamine effect

Protamine + heparin

Chemical antagonism

Reversal of heparin anticoagulation

Opioid + benzodiazepine/alcohol

Combined CNS depression

Sedation and respiratory depression

24. Take-Home Points

  • Pharmaceutical interactions: Occur before administration.

  • PK interactions: Change exposure through ADME, often involving enzymes or transporters.

  • PD interactions: Change effects without necessarily changing drug concentration.

  • Enzyme inhibition can increase toxicity or reduce activation and efficacy.

  • Protein displacement alone rarely explains a sustained interaction.

  • A single drug can be affected by several enzymes, transporters, and precipitants.

  • Good interaction assessment connects mechanism → patient risk → expected consequence → monitoring plan.